

**APPLICANTS:** Vickers et al.  
**SERIAL NO:** 10/664,639


**DOCKET NO:** CORE0027US

**REMARKS**

Claims 1-84 were pending. Upon entry of this Amendment, claims 1-9, 18-26, 29-34, 50, 51, 56-60, 63, 69-75, 77, 79-107 will be pending. Claims 10-17, 27, 28, 35-49, 52-55, 61, 62, 64-68, 76 and 78 are canceled and new claims 85-107 are submitted herein. Basis for the new claims can be found throughout the specification and claims as originally filed, such as, for example, at pages 50-53 of the specification. No new matter has been added to the claims. Applicants reserve the right to file subsequent applications claiming the canceled subject matter.

An early Office Action on the merits is earnestly solicited. The Examiner is invited to contact Applicants' undersigned representative at the number below if there are any questions regarding Applicants' claimed invention.

Respectfully submitted,

  
**Jodi L. Connolly, Ph.D.**  
Registration No. 54,044

**Date:** May 25, 2006

ISIS Pharmaceuticals, Inc.  
1896 Rutherford Rd.  
Carlsbad, CA 92008  
Telephone: (760) 603-2777  
Facsimile: (760) 603-3820